5AM Venture Management, LLC

In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), 5AM Venture Management, LLC reported 28 stock positions worth $447.1 million. Its top holding was Skye Bioscience (SKYE) at 18.2% of the portfolio, followed by Entrada Therapeutics (TRDA, 14.1%) and Enliven Therapeutics (ELVN, 13.6%). Compared with Q1 2024, it opened 4 new positions, sold out of 2, added to 1 and reduced 2. The biggest buy was a new position in Skye Bioscience (SKYE) and the biggest sale an exit from Merus (MRUS).

Most Recent 13F
Q2 2026
Location
SAN FRANCISCO, CA
CIK
0001799883
Portfolio Value
$447.1M (Q2 2024)
SEC Filing
0001104659-24-089661 ↗ filed Aug 14, 2024

Holdings Value

0$100.0M$200.0M$300.0M$400.0M$500.0M Q1 2024: $446.6M Q1 2024 Q2 2024: $447.1M $447.1M Q2 2024 Q3 2024: $484.0M Q3 2024 Q4 2024: $419.1M Q4 2024 Q1 2025: $264.4M Q1 2025 Q2 2025: $260.1M Q2 2025 Q3 2025: $273.0M Q3 2025 Q4 2025: $318.1M Q4 2025 Q1 2026: $360.2M Q1 2026 Q2 2026: $287.9M Q2 2026

Holdings 28 stocks · $447.1M
SKYE Skye Bioscience Inc. 18.24% 10,179,505 $81.5M New
TRDA Entrada Therapeutics Inc. 14.05% 4,408,379 $62.8M No change
ELVN Enliven Therapeutics Inc. 13.65% 2,610,875 $61.0M Reduce -31.9%
DNTH Dianthus Therapeutics Inc. 7.14% 1,232,965 $31.9M Reduce -0.7%
CLDX Celldex Therapeutics Inc. 4.12% 497,270 $18.4M No change
BHVN Biohaven Ltd. 3.65% 469,972 $16.3M Add +46.9%
TYRA Tyra Biosciences Inc. 3.36% 939,298 $15.0M No change
PHVS Pharvaris NV 3.35% 797,600 $15.0M No change
PRAX Praxis Precision Medicines I 3.15% 340,000 $14.1M No change
ERAS Erasca Inc. 2.85% 5,405,404 $12.8M New
VKTX Viking Therapeutics Inc. 2.82% 237,560 $12.6M No change
MLTX Moonlake Immunotherapeutics 2.78% 282,313 $12.4M No change
CNTA Centessa Pharmaceuticals Ltd. 2.51% 1,245,000 $11.2M No change
TECX Tectonic Therapeutic Inc. 2.38% 646,524 $10.6M New
VRDN Viridian Therapeutics Inc. 2.14% 736,595 $9.6M No change
SLN Silence Therapeutics PLC-ADR 2.02% 476,200 $9.0M No change
ANAB Anaptysbio Inc. 2.01% 357,733 $9.0M No change
GHRS GH Research PLC 1.49% 572,665 $6.7M No change
COGT Cogent Biosciences Inc. 1.49% 790,440 $6.7M No change
VOR Vor Biopharma Inc. 1.42% 6,361,723 $6.4M No change
SCPH Scpharmaceuticals Inc. 1.17% 1,200,647 $5.2M No change
RLYB Rallybio Corp. 1.09% 3,630,724 $4.9M No change
QTTB Q32 Bio Inc. 1.01% 251,994 $4.5M No change
ADVM Adverum Biotechnologies Inc. 0.83% 541,666 $3.7M No change
MERSANA THERAPEUTICS INC 0.59% 1,305,000 $2.6M No change
ZNTL Zentalis Pharmaceuticals Inc. 0.45% 490,000 $2.0M No change
CDTX Cidara Therapeutics Inc. 0.15% 56,725 $677K No change
EYPT Eyepoint Inc. 0.10% 50,000 $435K New

Portfolio Sells Q1 2024 → Q2 2024
MRUS Merus NV Sold out 0.00% −5.53
RNAM Avidity Biosciences Inc. Sold out 0.00% −3.80
ELVN Enliven Therapeutics Inc. Reduce -31.9% 13.65% −1.46
DNTH Dianthus Therapeutics Inc. Reduce -0.7% 7.14% −1.21

Portfolio Buys Q1 2024 → Q2 2024
SKYE Skye Bioscience Inc. New 18.24% +18.24
ERAS Erasca Inc. New 2.85% +2.85
TECX Tectonic Therapeutic Inc. New 2.38% +2.38
EYPT Eyepoint Inc. New 0.10% +0.10
BHVN Biohaven Ltd. Add +46.9% 3.65% −0.27

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 16$287.9MMPLT, TYRA, TRDA, PHVS, CAMP
Q1 2026 20$360.2MERAS, TRDA, TYRA, CAMP, CNTA
Q4 2025 21$318.1MTRDA, CAMP, TYRA, VRDN, PHVS
Q3 2025 25$273.0MSKYE, TRDA, PHVS, CAMP, CNTA
Q2 2025 29$260.1MSKYE, TRDA, DNTH, ELVN, PHVS
Q1 2025 31$264.4MTRDA, ELVN, DNTH, SKYE, PHVS
Q4 2024 31$419.1MTRDA, ELVN, SKYE, TECX, ARTV
Q3 2024 28$484.0MTRDA, ELVN, SKYE, ARTV, DNTH
Q2 2024 28$447.1MSKYE, TRDA, ELVN, DNTH, CLDX
Q1 2024 26$446.6MELVN, TRDA, DNTH, MRUS, CLDX